Differences underlying EGFR and HER2 oncogene addiction.
作者信息
Faber Anthony C, Wong Kwok-Kin, Engelman Jeffrey A
出版信息
Cell Cycle. 2010 Mar 1;9(5):851-2. doi: 10.4161/cc.9.5.11096. Epub 2010 Mar 30.
Abstract
摘要
相似文献
1
Differences underlying EGFR and HER2 oncogene addiction.
Cell Cycle. 2010 Mar 1;9(5):851-2. doi: 10.4161/cc.9.5.11096. Epub 2010 Mar 30.
2
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Breast Cancer Res. 2013;15(5):R85. doi: 10.1186/bcr3480.
3
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
Cancer Discov. 2011 Sep;1(4):352-65. doi: 10.1158/2159-8290.CD-11-0106. Epub 2011 Jul 22.
4
Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.
PLoS One. 2013 Oct 4;8(10):e77270. doi: 10.1371/journal.pone.0077270. eCollection 2013.
5
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Clin Exp Metastasis. 2008;25(8):843-54. doi: 10.1007/s10585-008-9200-4. Epub 2008 Aug 12.
6
Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
Br J Cancer. 2011 Sep 6;105(6):807-13. doi: 10.1038/bjc.2011.322. Epub 2011 Aug 16.
7
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Clin Cancer Res. 2013 Oct 1;19(19):5390-401. doi: 10.1158/1078-0432.CCR-13-1038. Epub 2013 Aug 15.
8
A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.
Oncogene. 2012 Jun 7;31(23):2888-98. doi: 10.1038/onc.2011.460. Epub 2011 Oct 10.
9
HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.
10
PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
Sci Rep. 2019 Apr 5;9(1):5692. doi: 10.1038/s41598-019-42245-3.
引用本文的文献
1
DARPin_9-29-Targeted Gold Nanorods Selectively Suppress HER2-Positive Tumor Growth in Mice.
Cancers (Basel). 2021 Oct 19;13(20):5235. doi: 10.3390/cancers13205235.
2
Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Cell Oncol (Dordr). 2019 Jun;42(3):369-380. doi: 10.1007/s13402-019-00432-4. Epub 2019 Feb 20.
3
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.
Cancers (Basel). 2017 Apr 12;9(4):33. doi: 10.3390/cancers9040033.
4
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Mol Carcinog. 2016 May;55(5):991-1001. doi: 10.1002/mc.22342. Epub 2015 Jun 4.
5
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.
Cancer Discov. 2015 May;5(5):475-87. doi: 10.1158/2159-8290.CD-15-0011. Epub 2015 Apr 20.
6
A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells.
Cell Death Dis. 2015 Mar 12;6(3):e1686. doi: 10.1038/cddis.2015.25.
7
Identification of drivers from cancer genome diversity in hepatocellular carcinoma.
Int J Mol Sci. 2014 Jun 20;15(6):11142-60. doi: 10.3390/ijms150611142.
8
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.
Cancer Cell. 2014 Mar 17;25(3):282-303. doi: 10.1016/j.ccr.2014.02.025.
9
Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma.
PLoS One. 2013 Nov 13;8(11):e80665. doi: 10.1371/journal.pone.0080665. eCollection 2013.
10
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer.
ISRN Oncol. 2012;2012:428062. doi: 10.5402/2012/428062. Epub 2012 Nov 22.
本文引用的文献
1
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19503-8. doi: 10.1073/pnas.0905056106. Epub 2009 Oct 22.
2
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
3
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.
4
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
PLoS One. 2008 Aug 26;3(8):e3065. doi: 10.1371/journal.pone.0003065.
5
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Clin Cancer Res. 2008 May 15;14(10):2895-9. doi: 10.1158/1078-0432.CCR-07-2248.
6
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
Curr Opin Genet Dev. 2008 Feb;18(1):73-9. doi: 10.1016/j.gde.2008.01.004. Epub 2008 Mar 5.
7
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26.
8
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.
Cancer Cell. 2006 May;9(5):351-65. doi: 10.1016/j.ccr.2006.03.027.
9
Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.
Oncogene. 2003 Oct 2;22(43):6785-93. doi: 10.1038/sj.onc.1206792.
Zotero 插件